Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited reported a significant 69% increase in net revenues for its product Ryoncil® in the second quarter following its launch, driven by increased physician adoption and reimbursement from commercial and government payers. The assignment of a permanent J-Code by the Centers for Medicare and Medicaid Services is expected to further enhance product adoption. The company has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. Mesoblast is also planning a pivotal trial for Ryoncil® in adults with severe SR-aGvHD, potentially expanding its market reach. The company holds a strong cash position and is exploring additional funding options to support its operations and growth.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines aimed at treating severe and life-threatening inflammatory conditions. The company specializes in mesenchymal lineage cell therapy technology, which targets severe inflammation by releasing anti-inflammatory factors. Mesoblast’s flagship product, Ryoncil®, is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease (SR-aGvHD). The company is also advancing therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: -15.48%
Average Trading Volume: 5,112,045
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.36B
See more data about MSB stock on TipRanks’ Stock Analysis page.